Background Atopic dermatitis (AD) is a chronic, recurrent inflammatory skin disease with a complex etiology involving genetic, environmental, and immunologic factors. In recent years, the influence of diet on AD has attracted widespread attention. However, the relationship between dietary components and AD remains complex and requires further investigation. Methods Up until October 2024, a thorough literature search was conducted using the internet databases of Web of Science, Cochrane, PubMed, and Scopus. The following keywords were used in the search strategy: “Atopic Dermatitis,” “Nutrition,” “Nutrients,” “Dietary Factors,” “Fatty Acids,” “Vitamin,” “Mineral,” “Zinc,” “Iron,” “Nickel,” “Probiotics,” “Prebiotics,” “Synbiotics,” “Breastfeeding,” “Maternal Diet,” “Phytochemicals,” “Polyphenol,” “Mediterranean Diet,” “Vegan Diet,” “Plant‐Based Diet,” “Gluten,” “Food Allergies,” “Elimination Diets,” “Dietary Exclusion,” and “Food Elimination.” This review systematically evaluates the literature on the impact of various dietary and nutritional factors on AD. Results The prevention or management of AD may benefit from a number of nutritional factors, including fatty acids, vitamins, minerals, probiotics, prebiotics, synbiotics, phytochemicals, and gluten, as well as dietary patterns, including breastfeeding, the Mediterranean diet, vegan diets, and elimination diets. By enhancing skin barrier function, lowering inflammatory responses, and modifying immunological responses, these nutrients and dietary strategies may help prevent and manage AD. However, the evidence currently available to support generalized dietary interventions as standard treatment for AD is still insufficient. Conclusion There are still a lot of inconsistencies in the research on the relationship between nutrients and AD. This review aims to inform future research and clinical practice in the management of AD and explore the potential of nutritional interventions in managing AD.

Background Malignant atrophic papulosis (MAP) is the systemic subtype of Degos disease, characterized by high lethality. Currently there is no standardized treatment protocol. Steroids and immunosuppressive therapies result in limited effectiveness. Biologic treatments offer promising therapeutic potential for MAP and significantly improve prognosis. Aims This review aims to systematically evaluate the applications of various biologics in the treatment of MAP and to explore their potential efficacy. Methods We systematically searched three electronic databases (Scopus, Embase, and PubMed) from inception to November 30, 2025. All cases involving biologics for the treatment of MAP were included and analyzed. Results A total of six different biologics have been utilized in the treatment of MAP. Among all the biologics, eculizumab demonstrated the highest response rate, reaching 76.5% ( n = 13/17). The use of rituximab has yielded inconsistent outcomes in the treatment of MAP. Neither tocilizumab nor natalizumab demonstrated satisfactory therapeutic efficacy, while the use of TNF inhibitors may result in disease exacerbation. Conclusion Eculizumab is recommended as a potential salvage therapy, and its combination with treprostinil may result in longer disease remission time. TNF inhibitors should be avoided in patients with MAP. More studies are needed to assess the long‐term safety and efficacy of biologics in the treatment of MAP.

Prurigo nodularis (PN) is a distinct chronic, inflammatory, neuroimmune‐mediated skin condition characterized by pruritic, often symmetrically distributed nodules, papules, and/or plaques. Recognition of PN as a distinct entity is complicated by the absence of a precise disease definition, uncertain epidemiologic estimates, and limited assessments of disease burden. The aim of this review is to provide a critical overview of global epidemiologic data of PN and current disease definitions. The available diagnostic criteria and assessment tools to determine disease severity for PN are examined. The psychosocial and healthcare burden of PN is also reviewed. Finally, other prevailing shortcomings in this therapeutic area are discussed, including the need for a standardized treatment algorithm for PN using currently available therapies, a greater understanding of disease pathophysiology, and the development of new targeted therapies for PN.

Folliculotropic mycosis fungoides (FMF) is a rare subtype of MF, characterized by prominent folliculotropism in histopathology. Clinically, FMF exhibits polymorphic presentations, mainly including follicular papules, plaques, alopecia, and other nonspecific lesions, with a predilection for the head and neck region, leading to frequent misdiagnosis. Historically, FMF was perceived as an aggressive subtype with an unfavorable prognosis, often regarded as advanced‐stage MF requiring aggressive combination therapies. However, recent studies have identified a subset of FMF with indolent progression and favorable prognosis, which can achieve remission through skin‐directed therapies (SDTs). Therefore, FMF treatment strategies should follow the stage‐adapted principles such as classical MF, with individualized regimens based on disease staging. This review comprehensively elaborates the diagnostic criteria and clinicopathological staging system of FMF, with a focus on stage‐based therapeutic principles, aiming to guide clinical practice.

Background Pyogenic paronychia with granulation tissue usually requires surgical intervention and preoperative inflammation control. We developed a modified surgical procedure (the mini‐Winograd procedure) and an innovative method for preoperative inflammation control for such cases. Methods and Materials Between June 2022 and June 2023, 100 consecutive patients who underwent the mini‐Winograd procedure were retrospectively analyzed, including 43 patients with preoperative nail groove drainage and 57 patients with traditional preoperative treatment. Perioperative conditions were compared. Results Preoperative inflammation (42.1% vs. 7.0%, p < 0.001), postoperative edema (36.8% vs. 14.0%, p = 0.020), and postoperative pain (VAS: 3.2 ± 1.6 vs. 2.3 ± 1.2, p = 0.001) were significantly less in patients with preoperative nail groove drainage. Patients with drainage gained earlier recovery in walking ability (3.1 ± 1.0 vs. 2.7 ± 1.1, p = 0.035). The logistic regression results indicated that the preoperative inflammation status was an independent risk factor for SSI (OR = 11.67; p < 0.001) and postoperative severe pain (OR = 22.73; p = 0.003). Conclusion The mini‐Winograd procedure with preoperative nail groove drainage is an effective treatment for pyogenic paronychia with granulation tissue, which improves preoperative inflammation management, reduces postoperative pain, and enhances recovery.

Background Facial photoaging affects the health and quality of life of middle‐aged and elderly individuals. While energy‐based aesthetic technologies help delay aging, clinical evidence for home‐use devices remains limited. Objective To evaluate the clinical efficacy and safety of the Jmoon Transdermal Collagen Light Beauty Device for facial rejuvenation over a 12‐week period. Methods Thirty‐six healthy female volunteers with mild‐to‐moderate facial aging were recruited. The device’s effects on facial rejuvenation were assessed using VISIA imaging, PRIMOS‐CR 3D image analysis, Wood’s lamp, multifunctional skin testing, and skin ultrasound. Results Thirty‐four participants completed the study. After 12 weeks of continuous device use, significant improvements were observed in skin hydration (33.7% increase), firmness (21.7% increase), elasticity (22.0% increase), skin tone (39.9% increase), and brightness (8.0% increase) (all p < 0.0001). Sebum (49.6% reduction), melanin (22.0% reduction), and erythema (17.0% reduction) levels also decreased significantly (all p < 0.0001). PRIMOS‐CR 3D imaging showed significant reductions in wrinkle area, length, volume, and number (all p < 0.05). Skin ultrasound revealed a significant increase in dermal thickness ( p < 0.0001). The overall average pain score was 1.9 ± 1.7 based on a 0–10 Visual Analog Scale, with no severe adverse effects such as erythema, blisters, or pigmentation. Satisfaction scores indicated that the satisfaction rate reached 94.1%. Conclusion The Jmoon Transdermal Collagen Light Beauty Device significantly improved skin hydration, oil control, whitening, firmness, elasticity, and dermal thickness, while reducing erythema and wrinkles. It demonstrated a favorable safety profile and high user satisfaction in this exploratory study. Trial Registration: Chinese Registry of Clinical Trials: ChiCTR2400090845

Monogenic genodermatoses encompass a diverse group of over 400 distinct disorders, presenting significant therapeutic challenges. Recent advancements in the clinical application of biological agents have heralded a new era in the management of these conditions. A plethora of clinical studies and case reports have demonstrated the efficacy of TNF‐α, IL‐1, IL‐4Rα, IL‐17A, IL‐12/23, and IL‐6R inhibitors in the management of monogenic genodermatoses. To elucidate the current landscape of biological agent utilization and their putative mechanisms of action in the context of monogenic genodermatoses, we conducted a review of the literature.

Background Rosacea treatments often lead to recurrence after discontinuation, highlighting the need for effective maintenance therapies. The long‐term efficacy of treatments in preventing relapse has not been systematically compared. Objectives To compare the risk of relapse upon treatment discontinuation after achieving clinical remission with both topical and systemic therapies. Methods Updated systematic review and network meta‐analysis of randomized controlled studies following PRISMA guidelines. A thorough literature search across different databases to identify randomized controlled trials (RCTs) on treatment relapse rates in adult patients with moderate to severe papulopustular rosacea treated with systemic and topical treatments was conducted. Data were independently extracted, and the risk of bias was assessed using the Cochrane tool. Statistical analyses were performed using network meta‐analysis with random effects models. Results A total of seven out of an initial 14,450 articles screened were retrieved, involving 632 patients with moderate to severe rosacea and 552 controls treated with metronidazole 0.75% gel, doxycycline 40 mg, ivermectin 1% cream, isotretinoin 0.25 mg/kg/day, hydroxychloroquine 200 mg, and aminolevulinic acid photodynamic therapy. Results showed that isotretinoin and metronidazole significantly prevented rosacea relapse compared to placebo, with isotretinoin ranked as the most effective treatment according to SUCRA rankings. The average time regarding relapse varied among studies, with metronidazole showing a shorter relapse period (12 weeks) than ivermectin (21 weeks). The risk of bias was low, with no significant publication bias detected. The limits of this review were the relatively small number of studies included and the high degree of indirectness that was noted across these studies, potentially affecting the reliability of some estimates. Conclusion Rosacea remission can be maintained for a certain period of time after the discontinuation of the treatment and also during the treatments. Isotretinoin might be effective in reducing the risk of relapse.

Background Dupilumab has demonstrated promising efficacy and safety in patients with dystrophic epidermolysis bullosa (DEB). However, clinical data addressing its long‐term effectiveness and safety across diverse DEB subtypes remain limited. Objective To evaluate the long‐term effectiveness and safety of dupilumab in the treatment of various subtypes of DEB, especially severe DEB. Methods This retrospective study analyzed patients with DEB who received dupilumab therapy at Henan Provincial People’s Hospital between January 2021 and October 2023. Results Twelve patients with five subtypes of DEB (Intermediate DDEB, Severe RDEB, Intermediate RDEB, DDEB Pruriginosa, and RDEB Pruriginosa) were enrolled. Genetic analysis of COL7A1 was performed and identified 8 new mutations, including c.7720_7721insG, c.313_1834del, dsIVS15 + 1G > T, c.6082G > A, c.6191G > A, c.7697G > A, c.7087G > A, and c.8662_8677del. Eosinophil count tests were normal in all patients, and serum total IgE was elevated in 7/12 patients. The mean baseline BEBS score (23.86 ± 15.77) declined progressively to 16.35 ± 12.50, 12.34 ± 9.91, and 10.4 ± 9.09 at the 16‐week, 24‐week, and 52‐week follow‐ups, respectively. The mean baseline NRS pruritus score of all patients was 7.25 ± 0.97, and it decreased to 3.83 ± 1.47 and 1.82 ± 0.89 at the 4‐week and 52‐week follow‐ups, respectively. The mean baseline DLQI score of all patients was 19.12 ± 6.21, and it decreased to 10.36 ± 6.19, 5.82 ± 3.37, and 5.00 ± 3.00 at the 16‐week, 24‐week, and 52‐week follow‐ups, respectively. BEBS, NRS pruritus, and DLQI baseline scores were statistically significant differences from those after 52 weeks of treatment ( p < 0.01). Of the 12 DEB patients, Patient #6 had a poor treatment effect and Patient #12 had transient conjunctivitis. Notably, five patients maintained sustained treatment efficacy without significant adverse events for over two years. Conclusion Dupilumab showed long‐term effectiveness and safety in real‐world practice in 11 Chinese patients with five subtypes of DEB (Intermediate DDEB, Severe RDEB, Intermediate RDEB, DDEB Pruriginosa, and RDEB Pruriginosa).